Skip to main content
Clinical Trials/RBR-5q4gm5b
RBR-5q4gm5b
Recruiting
Phase 3

Double-blind, randomized, controlled study on the effect of Sacubitril/Valsartan in the prevention of cardiotoxicity in high-risk patients undergoing chemotherapy with anthracyclines

Hospital Erasto Gaertner0 sitesMarch 7, 2022

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Hospital Erasto Gaertner
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 7, 2022
End Date
February 28, 2025
Last Updated
2 years ago
Study Type
Intervention

Investigators

Sponsor
Hospital Erasto Gaertner

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with cancer who will undergo chemotherapy with anthracyclines and who have an increase in ultrasensitive troponin I above the 99th percentile after any chemotherapy session; age over 18 years; patients who sign the Free and Informed Consent Term

Exclusion Criteria

  • Inability to analyze ventricular function; claustrophobia; history of chemotherapy or radiotherapy; previous symptoms of heart failure; presence of cardiomyopathy ou coronary artery disease; moderate to severe aortic or mitral valve disease; contraindication to the use of Sacubitril/Valsartan such as a history of angioedema, renal artery stenosis; creatinine clearance \<30ml/min/m2; serum potassium \>5\.0mEq/L; pregnant women; systolic blood pressure \<100mmHg; use of angiotensin converting enzyme inhibitor, angiotensin receptor blocker, Sacubitril/Valsartan, or beta\-blocker; implantation of pacemaker not compatible with MRI; patients with HER 2 expression; patients with frailty or at medium\-high risk of hospitalization with substantial change in chemotherapy regimen

Outcomes

Primary Outcomes

Not specified

Similar Trials